Pfizer Inc.; market cap as of 27/11/2015: $202.7bn Allergan plc; market cap as of 27/11/2015: $126bn Introduction On November 23, 2015, Pfizer Inc. (NYSE: PFE) and Allergan plc (NYSE: AGN) announced that their boards of directors have unanimously approved a definitive merger agreement under which Pfizer will combine with Read more…
Shire PLC; market cap: $28.38bn (as of 06/11/2015) Dyax Corporation; market cap: $5.1bn (as of 06/11/2015) Introduction On November 2, Dublin-headquartered pharmaceutical company Shire Plc agreed to acquire the Massachusetts-based biopharma company Dyax Corporation for an upfront cash consideration of $5.9bn and an additional $646m payment contingent on the Read more…
Walgreens Boots Alliance; market cap (as of 30/10/2015) $91.3bn Rite Aid; market cap (as of 30/10/2015) $8.2bn Introduction Last week the pharma sector was shook up by a new deal: Walgreens Boots Alliance agreed to buy the smaller pharma rival Rite Aid in a transaction worth $17.2bn. The deal Read more…
Teva Pharmaceuticals Industries Ltd. (TEVA); market cap (as of 02/10/2015): $51.05bn. Introduction Following a wave of consolidation in the healthcare industry, Teva Pharmaceuticals Industries Ltd. and Representaciones e Investigaciones Médicas, S.A. de C.V. (Rimsa) announced on October 1 that they have entered into a definitive agreement under which Teva Read more…
Teva Pharmaceutical Industries ; Market Cap (as of 25/04/2015): $62,67bn Mylan Pharmaceuticals ; Market Cap (as of 25/04/2015): $36,06bn Introduction In the healthcare industry, the saying “eat or be eaten” no longer applies. Instead, the adage of “make a bid or wait for an offer” would be more appropriate Read more…
AbbVie Inc.; market cap (as of 06/03/2015): $88.7bn Pharmacyclics Inc.; market cap (as of 06/03/2015): $19.3bn Introduction On March 4, the pharmaceutical company AbbVie, outbidding the competitor Johnson & Johnson, agreed to buy the cancer biotech company Pharmacyclics in a $21bn transaction. The Chicago based company will pay $261.25 per Read more…
Pfizer Inc.; market cap (as of 20/02/2015): US$217.75bn Hospira Inc.; market cap (as of 20/02/2015): US$14.97bn Introduction On February 5th, 2014, pharmaceutical behemoth Pfizer signed with Hospira, the world’s leading provider of injectable drugs and biosimilars, a definitive merger agreement which consists of the fully acquisition of Hospira for US$90 Read more…
Actavis plc.; market cap (as of 21/11/2014): $70.5bn Allergan Inc.; market cap (as of 21/11/2014): $63.3bn Introduction The growing emphasis we put on health and quality of life, and the scientific advancements which are making this possible, are putting the pharmaceutical and medical industries in the spotlight. The recent surge Read more…
Pfizer Inc, Market Cap (as of 23/05/2014): $188.37bn AstraZeneca PLC, Market Cap (as of 23/05/2014): $91.78bn In its bid for AstraZeneca, Pfizer, the famous Viagra producer, failed to make a satisfactory offer and turned the potential biggest foreign takeover in UK corporate history into failure. It all happened on May Read more…
The European debt crisis seems to have taken the way of recovery and the rates for European government bonds reflect a positive economic outlook in the Euro area. The Euro Stoxx 50 Index includes Europe’s leading Blue-chips companies. Actually, these companies are considered as safe as AAA European countries (Germany, Read more…